Bone Abstracts

Oftenly, the question arises whether anti-osteoporotic drugs should be prescribed in glucocorticoid-treated premenopausal women. On the one hand, there are strong arguments to prescribe these drugs, when these patients are treated with high dose glucocorticoïds, and suffer from diseases that have a negative effect on bone, for instance SLE.

On the other hand, the absolute fracture risk is low, related to their young age, and finally, in women with childbearing potential, the possible negative effect of long-acting bisphosphonates should be discussed.

Prof Cyrus Cooper will present the evidence, and I will present shortly some background data and focus on some cases, and hope for an open and lively discussion!